Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorde Melo Gagliato, Debora
dc.contributor.authorBuzaid, Antonio C
dc.contributor.authorPerez-Garcia, Jose Manuel
dc.contributor.authorLlombart-Cussac, Antonio
dc.contributor.authorCortés Castan, Javier
dc.date.accessioned2021-08-26T11:40:50Z
dc.date.available2021-08-26T11:40:50Z
dc.date.issued2020-09-01
dc.identifier.citationde Melo Gagliato D, Buzaid AC, Perez-Garcia JM, Llombart A, Cortes J. CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge. Cancers. 2020 Sep 1;12(9):2480.
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11351/6241
dc.descriptionCDK4/6 inhibitors; Hormone receptor-positive breast cancer; Metastatic breast cancer
dc.description.abstractTreatment paradigms in advanced hormone receptor (HR)-positive breast cancer were substantially transformed with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) approval. The addition of these drugs to endocrine treatment profoundly improved progression-free and overall survival. Additionally, other important endpoints, such as the response rate, time to chemotherapy, and a delay in quality of life deterioration, were positively impacted by CDK4/6 inhibitors’ addition to the treatment of advanced HR-positive breast cancer. This review article will summarize current knowledge on CDK4/6 inhibitors in clinical practice for advanced HR-positive metastatic breast cancer, as well as describe recent efforts to more precisely characterize mechanisms of sensitivity and resistance to these drugs, both on the molecular and clinical characterization level.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;12(9)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMama - Càncer
dc.subjectMedicaments antineoplàstics - Ús terapèutic
dc.subject.meshBreast Neoplasms
dc.subject.meshAntineoplastic Agents
dc.subject.mesh/therapeutic use
dc.titleCDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers12092480
dc.subject.decsneoplasias de la mama
dc.subject.decsantineoplásicos
dc.subject.decs/uso terapéutico
dc.relation.publishversionhttps://www.mdpi.com/2072-6694/12/9/2480
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[de Melo Gagliato D] Centro Oncológico Antonio Ermírio de Moraes, Beneficência Portuguesa de São Paulo, São Paulo, Brazil. [Buzaid AC] Centro Oncológico Antonio Ermírio de Moraes, Beneficência Portuguesa de São Paulo, São Paulo, Brazil. Centro Oncológico Hospital Israelita Albert Eisntein, São Paulo, Brazil. [Perez-Garcia JM, Llombart A] Baselga Institute of Oncology, Quiron University Hospital Barcelona, Barcelona, Spain. [Cortes J] Ramon y Cajal University Hospital, Madrid, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid32882980
dc.identifier.wos000581446700001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record